Cerebrovascular Disorders Associated with Ph-Negative Myeloproliferative Diseases

Background. Cerebrovascular disorders continue to be among the most common and socially signifi cant worldwide. Among multiple reasons for circulatory disturbances special importance is attached to hemorheology and hemostasis disorders occurring also in patients with Ph-negative myeloproliferative diseases (MPD). Aim. To investigate typical characteristics of the course of cerebrovascular disorders in patients with Ph-negative MPD. Materials & Methods. The trial included 169 adult patients with neurological diseases. Among them the main group consisted of 104 patients aged 34 to 55 years (median 48.5 years) with Ph-negative MPD diagnosed at the National Research Center for Hematology. The control group consisted of 65 patients aged 51 to 58 years (median 55.5 years) with cerebrovascular diseases without concomitant hematological pathology. Results. The incidence of acute ischemic strokes was 26.2 % in polycythemia vera (PV), 20.5 % in essential thrombocythemia (ET), and 8.7 % in primary myelofi brosis (PMF). Conclusion. An acute ischemic stroke with a concurrent thrombotic occlusion of one of the major head arteries is a criterion for ruling out Ph-negative MPD. To identify cerebral lesions in patients with Ph-negative MPD (PV, ET, PMF) MRI of the brain is recommended.

• Publication year

  2019

• Venue

  Clinical oncohematology

• Publication date

  2019-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.21320/2500-2139-2019-12-4-398-405
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• АНТИАГРЕГАНТНАЯ ТЕРАПИЯ В ПРОФИЛАКТИКЕ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ

  2017cited by this paper
• [Diagnosis of latent polycythemia vera: A clinician's opinion].

  2016cited by this paper
• Клинические особенности цереброваскулярной патологии при ph-негативных миелопролиферативных заболеваниях

  2016cited by this paper
• The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

  2016cited by this paper
• Clinical Characteristics of Cerebrovascular Pathology with Patients Suffering from Ph-Negative Myeloproliferative Disease

  2016cited by this paper
• Polycythemia Vera: Literature Review and Own Data

  2015cited by this paper
• Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

  2015cited by this paper
• PATIENTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA

  2013cited by this paper
• Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk‐guided management

  2013cited by this paper
• Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).

  2012cited by this paper
• Подтипы ишемических нарушений мозгового кровообращения в молодом возрасте: диагностика и лечение

  2012cited by this paper
• The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

  2009cited by this paper
• Гемостаз, гемореология и атромбогенная активность сосудистой стенки в ангионеврологии

  2007cited by this paper
• Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.

  2007cited by this paper
• Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors.

  2006cited by this paper
• Pathogenesis of myelofibrosis with myeloid metaplasia.

  2005cited by this paper
• Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.

  2004cited by this paper

• No citing papers are available for this paper.